A Phase 1/2 interventional study of Pimasertib and Placebo in Metastatic Colorectal Cancer, sponsored by EMD Serono. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-19.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 2 under way, 1 of them phase 3. Colorectal Neoplasms · Merck KGaA, Darmstadt, Germany.
Among the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2010, is one of 3 in phase 1/2, and was the 9th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany is open now, in 12 countries. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 3
First in 2004; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 220 across the 15 interventional studies, 226 across the 6 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research trial is testing the experimental treatment pimasertib (MSC1936369B) in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects. The study will be run in two parts:
Part 1, or Safety Run-in Part: Will determine the maximum tolerated dose and the recommended Phase 2 dose (RP2D) of pimasertib combined with FOLFIRI as second-line treatment in subjects with metastatic K Ras mutated colorectal cancer.
Part 2 or Phase 2 Randomised Part: Will assess the anti-tumor activity of pimasertib combined with FOLFIRI compared to FOLFIRI with placebo as second-line treatment in metastatic K Ras mutated colorectal cancer subjects.
Phase I which Is an open label dose escalation "3+3" cohort, non-randomized, safety Phase II which is a double blind randomized safety/efficacy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Safety Run-in and Part 2 or Phase 2 Randomised Part
Exclusion Criteria:
For Safety Run-in and Part 2 or Phase 2 Randomised Part
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib · Drug: FOLFIRI
Planned, not performed
Drug: Pimasertib · Drug: FOLFIRI
Planned, not performed
Drug: Placebo · Drug: FOLFIRI
Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Also known as: MSC1936369B
Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)
MTD was defined as the dose level, at which the treatment-related dose limiting toxicity (DLT) occurred in \>1 of 3 subjects or in \>1 of 6 subjects. DLT was defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Any Grade \>=3 non-hematological toxicity except for Grade 4 asymptomatic increases in liver function tests (LFTs) reversible within 7 days in subjects with liver involvement, Grade 3 asymptomatic increases in LFTs reversible within 7 days in subjects without liver involvement, Grade 3 vomiting controlled with adequate and optimal therapy and prophylaxis, and Grade 3 diarrhea controlled with adequate and optimal anti-diarrhea therapy; any Grade 4 neutropenia lasing \>5 days/ febrile neutropenia lasting \>1 day; any Grade 4 thrombocytopenia/Grade 3 with bleeding; any treatment delay \>2 weeks due to trial treatment-related adverse effects at any dose level and judged to be possibly or probably related to the trial treatment.
Time frame: Baseline up to Day 28 (Part 1)
Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS)
PFS was defined as time (in months) from the date of randomization to the first documentation of disease progression as reported and documented by the Investigator (i.e. radiological progression per RECIST v1.0) or death for any cause.
Time frame: From randomization up to first documented disease progression maximum up to 2 years
Part 1 or Safety Run-in Part: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From the first dose of study drug administration up to 28 days after the last dose of study drug administration
Part 1 or Safety Run-in Part: Maximum Observed Plasma Concentration (Cmax) of Pimasertib, Irinotecan and SN-38
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Time to Reach Maximum Observed Concentration (Tmax) of Pimasertib, Irinotecan and SN-38
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to the Time of Last Observation (AUC0-t) of Pimasertib, Irinotecan and SN-38
Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration is at or above the lower limit of quantification.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib, Irinotecan and SN-38
The AUC(0-inf) of pimasertib and irinotecan was estimated by determining the total area under the concentration time curve extrapolated to infinity.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Apparent Terminal Half Life (t1/2) of Pimasertib, Irinotecan and SN-38
The t1/2 was defined as the time required for the plasma concentration of pimasertib and irinotecan to decrease 50% in the final stage of elimination.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Apparent Oral Clearance (CL/f) of Pimasertib, (CL) Irinotecan and SN-38
Clearance of a drug was a measure of the rate at which drug was metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Apparent Oral Volume of Distribution (Vz f) Pimasertib, (Vz) of Irinotecan and SN-38
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Ratio of Cmax for Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Part 1 or Safety Run-in Part: Ratio of AUC0-inf of Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)
The AUC(0-inf) was estimated by determining the total area under the concentration time curve extrapolated to infinity.
Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan
Part 1 or Safety Run-in Part: Number of Subjects With Best Overall Response (BOR)
BOR was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
Time frame: Up to 2 years
Part 1 or Safety Run-in Part: Circulating Biomarkers in Serum
Time frame: Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years
Part 2 or Phase 2 Randomized Part: Circulating Biomarkers
Time frame: Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years
Part 2 or Phase 2 Randomized Part: Best Overall Response
BOR was defined based on Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
Time frame: Up to 2 years
Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAES between first dose of study drug administration and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From the first dose of study drug administration up to 28 days after the last dose of study drug administration
First/last subject (informed consent): March 2010/September 2011. Last subject completed:May 2012.
| Milestone | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Started | 10 | 6 |
| Completed | 10 | 6 |
| Not completed | 0 | 0 |
MTD was defined as the dose level, at which the treatment-related dose limiting toxicity (DLT) occurred in \>1 of 3 subjects or in \>1 of 6 subjects. DLT was defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Any Grade \>=3 non-hematological toxicity except for Grade 4 asymptomatic increases in liver function tests (LFTs) reversible within 7 days in subjects with liver involvement, Grade 3 asymptomatic increases in LFTs reversible within 7 days in subjects without liver involvement, Grade 3 vomiting controlled with adequate and optimal therapy and prophylaxis, and Grade 3 diarrhea controlled with adequate and optimal anti-diarrhea therapy; any Grade 4 neutropenia lasing \>5 days/ febrile neutropenia lasting \>1 day; any Grade 4 thrombocytopenia/Grade 3 with bleeding; any treatment delay \>2 weeks due to trial treatment-related adverse effects at any dose level and judged to be possibly or probably related to the trial treatment.
| mg | Pimasertib+FOLFIRI (Overall) |
|---|---|
| Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD) | 45 |
PFS was defined as time (in months) from the date of randomization to the first documentation of disease progression as reported and documented by the Investigator (i.e. radiological progression per RECIST v1.0) or death for any cause.
No measurements were reported for this outcome.
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Subjects | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| TEAE | 10 | 6 |
| Serious TEAE | 4 | 4 |
| TEAEs leading to discontinuation | 6 | 4 |
| TEAEs leading to death | 0 | 0 |
| nanogram per milliliter (ng/mL) | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=9, 6) | 145 (82.3 to 418) | 386 (163 to 516) |
| Pimasertib: Day 8 (n=9, 6) | 196 (71.6 to 660) | 332 (214 to 638) |
| Irinotecan: Day 1 (n=10, 6) | 2070 (1590 to 3060) | 1850 (1230 to 2110) |
| Irinotecan: Day 15 (n=8, 6) | 2120 (1760 to 2840) | 1540 (1330 to 2420) |
| SN-38: Day 1 (n=10, 6) | 20.4 (11.4 to 37.6) | 21.9 (15.8 to 46.3) |
| SN-38: Day 15 (n=8, 6) | 15.1 (9.28 to 37.5) | 27 (9.31 to 51.2) |
| hour | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=9, 6) | 2 (1.00 to 6.00) | 0.79 (0.50 to 4.00) |
| Pimasertib: Day 8 (n=9, 6) | 1.5 (0.53 to 2.00) | 1.25 (0.50 to 2.50) |
| Irinotecan: Day 1 (n=10, 6) | 1.5 (1.25 to 2.50) | 1.5 (1.50 to 2.50) |
| Irinotecan: Day 15 (n=8, 6) | 1.54 (1.50 to 2.50) | 1.56 (1.50 to 4.00) |
| SN-38: Day 1 (n=10, 6) | 1.5 (1.50 to 2.25) | 1.5 (1.50 to 4.00) |
| SN-38: Day 15 (n=8, 6) | 1.6 (1.50 to 2.50) | 2.5 (1.50 to 4.33) |
Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration is at or above the lower limit of quantification.
| (nanogram/milliliter)*hour([ng/mL]*hour) | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=9, 5) | 1120 (194 to 1860) | 1390 (666 to 2190) |
| Pimasertib: Day 8 (n=8, 5) | 1270 (190 to 2030) | 1260 (858 to 2060) |
| Irinotecan: Day 1 (n=10, 6) | 10500 (7130 to 18500) | 10200 (6220 to 11300) |
| Irinotecan: Day 15 (n=8, 6) | 12700 (7040 to 17900) | 11400 (7050 to 13400) |
| SN-38: Day 1 (n=10, 6) | 10500 (7130 to 18500) | 10200 (6220 to 11300) |
| SN-38: Day 15 (n=8, 6) | 12700 (7040 to 17900) | 11400 (7050 to 13400) |
The AUC(0-inf) of pimasertib and irinotecan was estimated by determining the total area under the concentration time curve extrapolated to infinity.
| ng/mL*hour | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=7, 5) | 1160 (226 to 1950) | 1430 (673 to 2310) |
| Pimasertib: Day 8 (n=8, 5) | 1340 (244 to 2140) | 1340 (869 to 2170) |
| Irinotecan: Day 1 (n=9, 6) | 10600 (7650 to 20600) | 11200 (6560 to 12500) |
| Irinotecan: Day 15 (n=8, 6) | 13600 (7330 to 20400) | 12300 (7520 to 14500) |
| SN-38: Day 1 (n=9, 6) | 10600 (7650 to 20600) | 11200 (6560 to 12500) |
| SN-38: Day 15 (n=8, 6) | 13600 (7330 to 20400) | 12300 (7520 to 14500) |
The t1/2 was defined as the time required for the plasma concentration of pimasertib and irinotecan to decrease 50% in the final stage of elimination.
| hour | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=7, 5) | 5.31 (2.37 to 5.97) | 5.56 (3.53 to 6.56) |
| Pimasertib: Day 8 (n=8, 5) | 5.12 (3.88 to 7.27) | 5.08 (4.27 to 6.25) |
| Irinotecan: Day 1 (n=9, 6) | 6.43 (5.32 to 7.63) | 6.83 (5.46 to 7.85) |
| Irinotecan: Day 15 (n=8, 6) | 6.21 (5.54 to 8.77) | 6.45 (5.59 to 7.21) |
| SN-38: Day 1 (n=9, 6) | 6.43 (5.32 to 7.63) | 6.83 (5.46 to 7.85) |
| SN-38: Day 15 (n=8, 6) | 6.21 (5.54 to 8.77) | 6.45 (5.59 to 7.21) |
Clearance of a drug was a measure of the rate at which drug was metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
| Liter per hour | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=7, 5) | 38.7 (23.1 to 199) | 42.1 (25.9 to 89.1) |
| Pimasertib: Day 8 (n=8, 5) | 34.2 (21.0 to 184) | 44.6 (27.6 to 69.1) |
| Irinotecan: Day 1 (n=9, 6) | 29.4 (16.4 to 47.0) | 29.7 (25.9 to 42.7) |
| Irinotecan: Day 15 (n=8, 6) | 23.5 (15.6 to 46.8) | 26.2 (20.9 to 37.3) |
| SN-38: Day 1 (n=9, 6) | 29.4 (16.4 to 47.0) | 29.7 (25.9 to 42.7) |
| SN-38: Day 15 (n=8, 6) | 23.5 (15.6 to 46.8) | 26.2 (20.9 to 37.3) |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
| Liter | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib: Day 1 (n=7, 5) | 276 (197 to 680) | 348 (210 to 570) |
| Pimasertib: Day 8 (n=8, 5) | 265 (189 to 1030) | 395 (246 to 425) |
| Irinotecan: Day 1 (n=9, 6) | 297 (147 to 455) | 313 (241 to 395) |
| Irinotecan: Day 15 (n=8, 6) | 212 (143 to 382) | 253 (182 to 336) |
| SN-38: Day 1 (n=9, 6) | 297 (147 to 455) | 313 (241 to 395) |
| SN-38: Day 15 (n=8, 6) | 212 (143 to 382) | 253 (182 to 336) |
| Ratio of Cmax | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib (n=8, 5) | 0.837 (0.345 to 1.18) | 0.751 (0.359 to 2.22) |
| Irinotecan (n=8, 6) | 0.973 (0.623 to 1.13) | 1.09 (0.774 to 1.40) |
| SN-38 (n=8, 6) | 0.973 (0.623 to 1.13) | 1.09 (0.774 to 1.40) |
The AUC(0-inf) was estimated by determining the total area under the concentration time curve extrapolated to infinity.
| Ratio | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Pimasertib (n=7, 4) | 0.917 (0.738 to 1.22) | 0.825 (0.759 to 1.21) |
| Irinotecan (n=8, 6) | 0.911 (0.577 to 1.08) | 0.844 (0.697 to 1.17) |
| SN-38 (n=8, 6) | 0.911 (0.577 to 1.08) | 0.844 (0.697 to 1.17) |
BOR was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
| Subjects | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| CR | 0 | 0 |
| PR | 1 | 1 |
| SD | 6 | 3 |
| PD | 1 | 2 |
| Not evaluable | 1 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
BOR was defined based on Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
No measurements were reported for this outcome.
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAES between first dose of study drug administration and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
No measurements were reported for this outcome.
Collected over From the first dose of study drug administration up to 28 days after the last dose of study drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | — | 4/10 (40%) | 10/10 (100%) |
| Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| Mucosal inflammationGeneral disorders | 0/10 | 2/6 |
| EnteritisGastrointestinal disorders | 0/10 | 1/6 |
| General physical health deteriorationGeneral disorders | 0/10 | 1/6 |
| PyrexiaGeneral disorders | 0/10 | 1/6 |
| Memory impairmentNervous system disorders | 0/10 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/6 |
| Intestinal obstructionGastrointestinal disorders | 1/10 | 0/6 |
| VomitingGastrointestinal disorders | 1/10 | 0/6 |
| AstheniaGeneral disorders | 1/10 | 0/6 |
| CardiomyopathyCardiac disorders | 1/10 | 0/6 |
| Event | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/10 | 5/6 |
| StomatitisGastrointestinal disorders | 2/10 | 5/6 |
| AstheniaGeneral disorders | 6/10 | 4/6 |
| VomitingGastrointestinal disorders | 4/10 | 4/6 |
| RashSkin and subcutaneous tissue disorders | 4/10 | 4/6 |
| NeutropeniaBlood and lymphatic system disorders | 2/10 | 4/6 |
| NauseaGastrointestinal disorders | 5/10 | 3/6 |
| Abdominal painGastrointestinal disorders | 3/10 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/10 | 3/6 |
| DyspepsiaGastrointestinal disorders | 0/10 | 2/6 |
The safety analysis set included all subjects who received at least one (non-zero) administration of the trial medication (any of the 3 FOLFIRI drugs and pimasertib).
| Age, Continuous(Years) | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI | Total |
|---|---|---|---|
| Mean | 62.3 ± 12.0 | 60.4 ± 17.2 | 61.6 ± 13.7 |
| Sex: Female, Male(Participants) | Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI | Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 5 | 4 | 9 |
The record gives a start of Mar 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib